- Home
- OPRA vs VRDN Comparison
OPRA vs VRDN Comparison
Compare OPRA & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OPRA | VRDN |
|---|---|---|
| Founded | 1996 | 2006 |
| Country | Norway | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.1B |
| IPO Year | 2018 | 2014 |
Fundamental Metrics
Financial Performance| Metric | OPRA | VRDN |
|---|---|---|
| Price | $17.67 | $21.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 14 |
| Target Price | $21.50 | ★ $35.46 |
| AVG Volume (30 Days) | 308.7K | ★ 1.1M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.61% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,706,000.00 |
| Revenue This Year | $21.29 | $13.73 |
| Revenue Next Year | $15.34 | $279.00 |
| P/E Ratio | $13.62 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.71 | $13.18 |
| 52 Week High | $21.06 | $34.29 |
Technical Indicators
Market Signals| Indicator | OPRA | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 40.83 | 47.00 |
| Support Level | $17.79 | $21.40 |
| Resistance Level | $19.43 | $23.84 |
| Average True Range (ATR) | 0.50 | 0.84 |
| MACD | -0.02 | -0.17 |
| Stochastic Oscillator | 40.56 | 28.11 |
Price Performance
Historical ComparisonAbout OPRA Opera Limited
Opera Ltd is a consumer internet software company providing a diversified portfolio of high-performance web browsers and adjacent digital services to engaged user base The company has transitioned from browser developer to multi-faceted platform offering a products and services that include PC and mobile browsers, its Opera Gaming portals and development tools, Opera News content platforms, Opera Ads platform, as well as a number of AI and web3 products and services, such as MiniPay and Opera AI, to a user base.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.